Do you want to read an article? Please log in or register.
CROWN: Persistent 7-year PFS benefits with lorlatinib versus crizotinib in advanced ALK-positive NSCLC
Lung, Respiratory and Thoracic Cancer
CHICAGO 2026
Related content
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Pronsati N, Liu G, Bauer TM, Felip E, Goto Y, Green G, Grizzard M, Hamel M, Mazieres J, Mok T, Snow S, Solomon BJ, Stratmann J, Culver K
doi: 10.1016/j.lungcan.2025.108662
Lung, Respiratory and Thoracic Cancer
Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database
Lung Cancer
Reale ML, Scattolin D, Vitale A, Passiglia F, Grisanti S, Macerelli M, Galetta D, Sini C, Minuti G, Citarella F, Roca E, Agustoni F, Dodi A, Cortinovis D, Belluomini L, Ricciardi S, Veccia A, Pizzutilo EG, Scotti V, Alì G, Mazzoni F, Russo A, Pignataro D, Bulotta A, Piovano P, Sergi C, Bettini A, Genova C, Pavan A, Soto Parra HJ, Ortega C, Pozzessere D, Vavalà T, Chiari R, Zannori C, D'Aveni A, Meoni G, Giannarelli D, Malapelle U, Novello S, Bria E, Pasello G
doi: 10.1016/j.lungcan.2025.108762
ELCC 2026
Lung, Respiratory and Thoracic Cancer
LBA1: LATIFY: No survival benefit with ceralasertib plus durvalumab versus docetaxel in patients with previously treated advanced NSCLC
WCLC 2025
Lung, Respiratory and Thoracic Cancer
EMPOWER-Lung 3: Cemiplimab plus chemotherapy provide sustained survival benefits in patients with advanced NSCLC
SABCS 2025
Breast Cancer
CAPItello-291: ctDNA analyses confirm benefit of capivasertib plus fulvestrant in HR-positive advanced breast cancer
CHICAGO 2026
Lung, Respiratory and Thoracic Cancer
LBA4: HARMONi-6: Ivonescimab plus chemotherapy significantly improved OS versus tislelizumab plus chemotherapy in previously untreated advanced squamous NSCLC
CHICAGO 2026
Genitourinary Cancer
EV-302: The 3.5-year update shows that enfortumab vedotin plus pembrolizumab maintains durable survival benefit over chemotherapy in advanced urothelial carcinoma
Lung, Respiratory and Thoracic Cancer
A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancer
Eur J Cancer
Byun JY, Kim J, Park S, Sun JM, Lee SH, Ahn JS, Ahn MJ, Kim JH, Lee EK, Jung HA
doi: 10.1016/j.ejca.2025.115805
ESMO 2025
Breast Cancer